2020-2027 Analysis and Review Deferasirox Market

Deferasirox Market

Deferasirox Market By Indication (Transfusional Hemosiderosis and Non-Transfusion-Dependent Thalassemia Syndromes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

19-03-2020 REP-HC-5052 40 Tables 110 pages Format

The deferasirox market was valued at USD2,353.4Mn by 2019. According to the latest statistics brought forward by the National Organization for Rare Disease (NORD), the annual incidence of symptomatic cases associated with beta-thalassemia major is 1 per 100,000 worldwide. A significant increase in the number of patients receiving frequent blood transfusion for the treatment of blood-related disorders will bolster the deferasirox market growth.

 Deferasirox Market

Deferasirox belongs to a category of iron chelating agents and is the first FDA approved drug for the treatment of chronic iron overload in patients receiving blood transfusion for a longer duration of time. It is available in different formulation for oral administration such as 90mg & 180mg film-coated tablets and tablet for suspension the composition are 125mg, 250mg, and 500mg, etc.

The major segments related to the deferasirox market are:

By Indication (2017–2027; US$ Mn)

Transfusional Hemosiderosis

Non-Transfusion-Dependent Thalassemia Syndromes

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy


Geography Segment(2017–2027; US$ Mn)

North America

United States


United Kingdom
Rest of Europe

Asia Pacific

Rest of Asia Pacific

Latin America (LATAM)

Rest of Latin America

Middle East and Africa (MEA)

Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global deferasirox market
  • The overall segmentation of the deferasirox market, by indication, distribution channel, and geography is minutely studied. Transfusional hemosiderosis and hospital pharmacy are dominating the indication and distribution channel segments respectively
  • Significant increase in the number of patients suffering with transfusional hemosiderosis
  • A constant rise in the number of non-transfusion-dependent thalassemia syndromes across all age group worldwide further accentuates the deferasirox market growth

Report gist?

  • The study of the global deferasirox market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in the manufacturing and marketing of deferasirox for the treatment of transfusional hemosiderosis worldwide
  • The report will benefit hematologists engaged in the prescription of deferasirox for the treatment of iron overload associated with blood-related disorders
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to deferasirox market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Transfusional hemosiderosis reigning the indication segment for deferasirox market. It is a medical condition in which there is a chronic iron overload in the liver, heart and other endocrine glands in the body of the patients who have received a blood transfusion for treating blood disorders such as sickle cell anemia, myelodysplastic syndrome, sickle cell anemia, etc. Deferasirox is recommended after the transfusion of 20 units of packed red blood cells or clinical evidence is reporting chronic iron overload for e.g. the serum ferritin level is greater than 1,000 µg/l associated with blood transfusion. Non-transfusion-dependent thalassemia syndromes will be the fastest-growing market during the forecast period chiefly due to a significant increase in the number of patients suffering from thalassemia syndromes. Chelation therapy is recommended after clinical evidence has reported the iron overload as serum ferritin levels consistently greater than 800 µg/l in patients suffering from thalassemia syndromes.

Hospital pharmacy is presently holding the largest market share in the distribution channel segment for deferasirox market. A different formulation of deferasirox for oral administration is vital in excreting the excess iron burden associated with blood transfusion. It is critical for the hospital pharmacist to adjust the dose per body weight in order to negate severe side effects such as renal and hepatic function disorders etc. Retail pharmacy is gaining solid grounds in the developing regions due to the presence of a lucrative market for generic versions of deferasirox available at affordable prices.

North America is presently dominating the geography segment for the deferasirox market. As per the latest research citings brought forward by the National Institute of Health (NIH), approximately 1% of the U.S. population is suffering from nonmalignant blood disorders. Domicile of major players such as Novartis AG, Apotex Corporation, Teva Pharmaceutical Industries Ltd., etc. further propels the deferasirox market growth in the region. The market growth in the Europe region is chiefly related to the significant increase in the number of patients suffering with non-transfusion-dependent thalassemia syndromes. As per the latest statistics provided by the Health Programme of The European Union, the annual incidence of symptomatic cases associated with beta-thalassemia in the European Union is 1 per 10,000 people. Asia Pacific is set to register comfortable market growth during the forecast period on account of the rising prevalence of blood disorders requiring frequent blood transfusions and the presence of lucrative generic drugs market in the region.

Select License Type


Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.